Beta Drugs Q4 FY26 Results: Announced May 14 2026 Generic Pharmaceuticals
- May 15, 2026
- Posted by: Neeraj Pandey
- Category: News
Beta Drugs Q4 results were announced on May 14, 2026, at the company’s board meeting. Q4 FY26 PAT approximately Rs 3 crore on revenue approximately Rs 40 crore. Generic pharmaceutical manufacturer focused on oncology drugs in the Rs 100-250 crore revenue range. Results filed with BSE on May 14, 2026. Specific financial data will be available from BSE filings after the board meeting. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.
Click Here – Get Free Investment Predictions
Beta Drugs Q4 FY26 Key Financial Highlights
| Metric | Q4 FY26 | Comparison |
|---|---|---|
| PAT (Net Profit) | Rs 3 crore | Q4 FY26 |
| Revenue from Operations | Rs 40 crore | Q4 FY26 |
| Ticker | BETADRUGS | Sector: Generic Pharmaceuticals |
Screen the best stocks on the Univest Screener.
Beta Drugs Performance Analysis
The company results reflect the company’s operational performance during the January to March 2026 quarter. the company results announced May 14, 2026. The company manufactures generic pharmaceutical formulations for anti-cancer, anti-infective, and other therapeutic segments. Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.
The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.
Beta Drugs FY27 Outlook
Post Beta Drugs, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Generic Pharmaceuticals space. The Beta Drugs results demonstrate the company’s execution capabilities. Track Beta Drugs updates on the Univest Screener for analyst views and FY27 earnings estimates.
Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.
Frequently Asked Questions on Beta Drugs Q4 FY26 Results
What is Beta Drugs Q4 FY26 PAT?
Ans. Beta Drugs Q4 FY26 PAT of Rs 3 crore (results declared May 14, 2026). Q4 FY26 PAT approximately Rs 3 crore on revenue approximately Rs 40 crore. Generic pharmaceutical manufacturer focused on oncology drugs in the Rs 100.
When did Beta Drugs announce Q4 FY26 results?
Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.
What is the FY27 outlook for Beta Drugs?
Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Generic Pharmaceuticals sector. Track live updates on the Univest Screener.
Where can I track Beta Drugs Q4 FY26 live data?
Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.
